Monopar Therapeutics financial data

Symbol
MNPR on Nasdaq
Location
1000 Skokie Blvd Suite 350, Wilmette, IL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 3.65 % -83.7%
Return On Equity -25.7 % +76.1%
Return On Assets -24.8 % +71.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.68M shares +26.6%
Common Stock, Shares, Outstanding 6.66M shares +89%
Entity Public Float 6.41M USD +39.2%
Common Stock, Value, Issued 6.66K USD +89%
Weighted Average Number of Shares Outstanding, Basic 7.12M shares +102%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.9M USD +286%
General and Administrative Expense 5.74M USD +99%
Operating Income (Loss) -21.6M USD -209%
Net Income (Loss) Attributable to Parent -19.4M USD -200%
Earnings Per Share, Basic -3 USD/shares -17.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 128M USD +2021%
Other Assets, Current 415K USD +737%
Assets, Current 144M USD +2274%
Operating Lease, Right-of-Use Asset 107K USD
Assets 144M USD +2276%
Liabilities, Current 2.57M USD
Operating Lease, Liability, Noncurrent 70.9K USD
Liabilities 2.64M USD +135%
Accumulated Other Comprehensive Income (Loss), Net of Tax 11.7K USD
Retained Earnings (Accumulated Deficit) -84.3M USD -30%
Stockholders' Equity Attributable to Parent 142M USD +2762%
Liabilities and Equity 144M USD +2276%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.66M USD -242%
Net Cash Provided by (Used in) Financing Activities -116K USD -104%
Net Cash Provided by (Used in) Investing Activities -326K USD +66.9%
Common Stock, Shares Authorized 40M shares 0%
Common Stock, Shares, Issued 6.66M shares +89%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.1M USD -1227%
Deferred Tax Assets, Valuation Allowance 17.9M USD +34.7%
Deferred Tax Assets, Gross 17.9M USD +34.7%
Operating Lease, Liability 102K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19.4M USD -198%
Lessee, Operating Lease, Liability, to be Paid 111K USD
Operating Lease, Liability, Current 31.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 43K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 43.8K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.56K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 10.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 4.48M USD +15.6%
Unrecognized Tax Benefits 412K USD +22.6%
Deferred Tax Assets, Net of Valuation Allowance 0 USD